Professionals Services Insights Community
About Offices Careers
Home / Insights / Approval Biosimilar Notice ...
PDF

08/03/2016 | Managing Intellectual Property Blog

Brian L. Klock

Approval Biosimilar Notice Implicates Millions

1 min

The Federal Circuit recently held that makers of biosimilars must always notify brand-name rivals six months before commercial product launch. Brian Klock and Kathryn Easterling report.
 
View Full PDF

Related Services

Practices

Related Insights

Sarepta Files Two IPRs Against Genzyme’s Patents Gene Therapy Elevidys® Allegedly Infringes
Sarepta Files Two IPRs Against Genzyme’s Patents Gene Therapy Elevidys® Allegedly Infringes

June 27, 2025

2min
Samsung Bioepis and Formycon’s EYLEA® IPRs Discretionarily Denied Institution Among Wave of Fintiv Denials; Regeneron Files Second BPCIA Lawsuit Against Amgen’s Pavblu™
Samsung Bioepis and Formycon’s EYLEA® IPRs Discretionarily Denied Institution Among Wave of Fintiv Denials; Regeneron Files Second BPCIA Lawsuit Against Amgen’s Pavblu™

June 26, 2025

6min
Intellectual Property Due Diligence "Red Flags"
Intellectual Property Due Diligence "Red Flags"

June 17, 2025

3min
View More

Events

Nuts and Bolts of Protecting Your IP
Nuts and Bolts of Protecting Your IP

July 16, 2025 Beverly Hills Bar Association

Register for the Event

Recent News

USA Today Quotes Kevin Ghassomian on Estate Planning Tips and Guidance
USA Today Quotes Kevin Ghassomian on Estate Planning Tips and Guidance

June 18, 2025

2min
Venable Experiences Featured in Attorney at Law’s Women in Law Special
Venable Experiences Featured in Attorney at Law’s Women in Law Special

June 18, 2025

6min
Venable’s New York Office Featured in Fordham Lawyer’s Profile of New Dean
Venable’s New York Office Featured in Fordham Lawyer’s Profile of New Dean

June 18, 2025

1min
View More